Skip to main content

Main menu

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Other Publications
    • cbm

User menu

  • My alerts

Search

  • Advanced search
Cancer Biology & Medicine
  • Other Publications
    • cbm
  • My alerts
Cancer Biology & Medicine

Advanced Search

 

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Follow cbm on Twitter
  • Visit cbm on Facebook
Review ArticleReview

The advanced development of molecular targeted therapy for hepatocellular carcinoma

Tao Yan, Lingxiang Yu, Ning Zhang, Caiyun Peng, Guodong Su, Yi Jing, Linzhi Zhang, Tong Wu, Jiamin Cheng, Qian Guo, Xiaoliang Shi and Yinying Lu
Cancer Biology & Medicine June 2022, 19 (6) 802-817; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0661
Tao Yan
1Comprehensive Liver Cancer Center, the 5th Medical Center of Chinese PLA General Hospital, Beijing 100039, China
2The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lingxiang Yu
3The Second Department of Hepatobiliary Surgery, Senior Department of Hepatology, the 5th Medical Center of Chinese PLA General Hospital, Beijing 100039, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ning Zhang
1Comprehensive Liver Cancer Center, the 5th Medical Center of Chinese PLA General Hospital, Beijing 100039, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caiyun Peng
1Comprehensive Liver Cancer Center, the 5th Medical Center of Chinese PLA General Hospital, Beijing 100039, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guodong Su
1Comprehensive Liver Cancer Center, the 5th Medical Center of Chinese PLA General Hospital, Beijing 100039, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi Jing
1Comprehensive Liver Cancer Center, the 5th Medical Center of Chinese PLA General Hospital, Beijing 100039, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linzhi Zhang
1Comprehensive Liver Cancer Center, the 5th Medical Center of Chinese PLA General Hospital, Beijing 100039, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tong Wu
1Comprehensive Liver Cancer Center, the 5th Medical Center of Chinese PLA General Hospital, Beijing 100039, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiamin Cheng
1Comprehensive Liver Cancer Center, the 5th Medical Center of Chinese PLA General Hospital, Beijing 100039, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qian Guo
2The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoliang Shi
4Shanghai OrigiMed Co., Ltd., Shanghai 201112, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Xiaoliang Shi
  • For correspondence: luyinying1973{at}163.com shixiaoliang{at}origimed.com
Yinying Lu
1Comprehensive Liver Cancer Center, the 5th Medical Center of Chinese PLA General Hospital, Beijing 100039, China
2The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China
5National Clinical Medical Research Center for Infectious Diseases, the 5th Medical Center of Chinese PLA General Hospital, Beijing 100039, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yinying Lu
  • For correspondence: luyinying1973{at}163.com shixiaoliang{at}origimed.com
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
Loading

Article Information

vol. 19 no. 6 802-817
DOI 
https://doi.org/10.20892/j.issn.2095-3941.2021.0661

Published By 
Cancer Biology & Medicine
History 
  • Received December 9, 2021
  • Accepted April 18, 2022
  • Published online July 15, 2022.

Copyright & Usage 
Copyright: © 2022, Cancer Biology & Medicine https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Author Information

  1. Tao Yan1,2,*,
  2. Lingxiang Yu3,*,
  3. Ning Zhang1,
  4. Caiyun Peng1,
  5. Guodong Su1,
  6. Yi Jing1,
  7. Linzhi Zhang1,
  8. Tong Wu1,
  9. Jiamin Cheng1,
  10. Qian Guo2,
  11. Xiaoliang Shi4⇑ and
  12. Yinying Lu1,2,5⇑
  1. 1Comprehensive Liver Cancer Center, the 5th Medical Center of Chinese PLA General Hospital, Beijing 100039, China
  2. 2The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China
  3. 3The Second Department of Hepatobiliary Surgery, Senior Department of Hepatology, the 5th Medical Center of Chinese PLA General Hospital, Beijing 100039, China
  4. 4Shanghai OrigiMed Co., Ltd., Shanghai 201112, China
  5. 5National Clinical Medical Research Center for Infectious Diseases, the 5th Medical Center of Chinese PLA General Hospital, Beijing 100039, China
  1. Corresponding to: Yinying Lu and Xiaoliang Shi, E-mail: luyinying1973{at}163.com and shixiaoliang{at}origimed.com
View Full Text

Cited By...

  • 53 Citations
  • Google Scholar
PreviousNext
Back to top

In this issue

Cancer Biology & Medicine: 19 (6)
Cancer Biology & Medicine
Vol. 19, Issue 6
15 Jun 2022
  • Table of Contents
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Cancer Biology & Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The advanced development of molecular targeted therapy for hepatocellular carcinoma
(Your Name) has sent you a message from Cancer Biology & Medicine
(Your Name) thought you would like to see the Cancer Biology & Medicine web site.
Citation Tools
The advanced development of molecular targeted therapy for hepatocellular carcinoma
Tao Yan, Lingxiang Yu, Ning Zhang, Caiyun Peng, Guodong Su, Yi Jing, Linzhi Zhang, Tong Wu, Jiamin Cheng, Qian Guo, Xiaoliang Shi, Yinying Lu
Cancer Biology & Medicine Jun 2022, 19 (6) 802-817; DOI: 10.20892/j.issn.2095-3941.2021.0661

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The advanced development of molecular targeted therapy for hepatocellular carcinoma
Tao Yan, Lingxiang Yu, Ning Zhang, Caiyun Peng, Guodong Su, Yi Jing, Linzhi Zhang, Tong Wu, Jiamin Cheng, Qian Guo, Xiaoliang Shi, Yinying Lu
Cancer Biology & Medicine Jun 2022, 19 (6) 802-817; DOI: 10.20892/j.issn.2095-3941.2021.0661
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Early diagnosis and treatment of HCC
    • Biomarkers for HCC diagnosis and prognostication
    • Advanced progress in targeted therapy for HCC
    • Advanced progress in immunotherapy in HCC
    • Conclusions and perspectives
    • Grant support
    • Conflict of interest statement
    • Author contributions
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies
  • Google Scholar

More in this TOC Section

  • Treatment implications of T cell DNA damage in anti-tumor immunity
  • Non-coding RNA delivery via lipid nanoparticles: a novel strategy for cancer immunotherapy
  • Pyroptosis in cancer: a dual regulator of tumor cell fate and immune activation
Show more Review

Similar Articles

Keywords

  • Hepatocellular carcinoma
  • precision medicine
  • liquid biopsy
  • targeted therapy
  • immunotherapy

Navigate

  • Home
  • Current Issue

More Information

  • About CBM
  • About CACA
  • About TMUCIH
  • Editorial Board
  • Subscription

For Authors

  • Instructions for authors
  • Journal Policies
  • Submit a Manuscript

Journal Services

  • Email Alerts
  • Facebook
  • RSS Feeds
  • Twitter

 

© 2026 Cancer Biology & Medicine

Powered by HighWire